Tomas Odergren
Net worth: 217 549 $ as of 2026-05-30
Net worth: 217 549 $ as of 2026-05-30
Dr. Tomas Odergren is a Chief Medical Officer at BioArctic AB and a Chairman at NovaSAID AB. Dr. Odergren was previously employed as a Vice President-Clinical Development by Karolinska Development AB, a Principal by AstraZeneca GmbH, and a Non-Executive Director by BioChromix Pharma AB. He also served on the board at Athera Biotechnologies AB, Forendo Pharma Oy, Modus Therapeutics AB, Modus Therapeutics Holding AB and Umecrine Cognition AB. He received his doctorate degree from Karolinska Institutet.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOARCTIC AB CLASS B 0.01% | 2024-12-30 | 5,700 ( 0.01% ) | 217 549 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| BIOARCTIC AB | Chief Tech/Sci/R&D Officer | 2018-12-31 |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology Develops treatments for inflammation and pain in conditions such as rheumatoid arthritis | Chairman | - |
| Companies | Position | End |
|---|---|---|
| KDVENTURES AB | Chief Tech/Sci/R&D Officer | 2014-10-31 |
AstraZeneca GmbH
AstraZeneca GmbH Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical drugs | Corporate Officer/Principal | 2012-10-11 |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Develops drug for neurological disorders of the brain | Director/Board Member | - |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage drug company that develops novel treatments in women’s health | Director/Board Member | - |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drug for the treatment of severe malaria and sickle cell disease | Director/Board Member | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Provides anti-inflammatory biological candidate drugs | Health Technology |
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioArctic AB
BioArctic AB Pharmaceuticals: MajorHealth Technology Develops drugs for patients with disorders of the central nervous systems | Health Technology |
AstraZeneca GmbH
AstraZeneca GmbH Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical drugs | Health Technology |
BioChromix Pharma AB
BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services Provides Alzheimer disease research services | Commercial Services |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Develops drug for neurological disorders of the brain | Health Technology |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology Develops treatments for inflammation and pain in conditions such as rheumatoid arthritis | Health Technology |
Karolinska Development AB
Karolinska Development AB Financial ConglomeratesFinance Operates as a life sciences investment company | Finance |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drug for the treatment of severe malaria and sickle cell disease | Health Technology |
Modus Therapeutics Holding AB
Modus Therapeutics Holding AB BiotechnologyHealth Technology Develops sevuparin to treat people suffering from sickle cell disease | Health Technology |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage drug company that develops novel treatments in women’s health | Health Technology |
Select your edition
All financial news and data tailored to specific country editions